drugset / Trial / NCT01105364
Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer
Diagnostic
Summary
RATIONALE: Diagnostic procedures, such as contrast-enhanced ultrasound, may help measure a patient's response to treatment with drugs such as sunitinib malate, sorafenib tosylate, or bevacizumab, and allow doctors to plan better treatment. PURPOSE: This clinical trial is studying ultrasonography in assessing antiangiogenic treatment in patients with advanced kidney cancer.
Timeline
- Start
- 2007-12
- Primary completion
- 2012-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | stabilized sulphur hexafluoride microbubble-based contrast agent | Unknown | — | — |